Genmab Signs an Agreement with Tempus to Develop Novel Targets and Biomarkers for Cancer Indications

Janssen Signs an Exclusive Worldwide License and Option Agreement with Genmab for its HexaBody-CD38


  • Tempus to receive milestones and royalties and has an option to fund part of product development programs in return of high royalty payments. Genmab and Tempus will jointly develop novel drugs and biomarkers for the novel concept identified by Genmab
  • The collaboration follows the expansion of their existing service agreement and will utilize Tempus’ technology platform and sequencing capabilities to discover cancer biomarkers. Genmab will lead all development and commercial activities
  • Tempus is focused on developing precision medicine by gathering and analyzing clinical and molecular data at scale and has built the world’s largest library of clinical and molecular data for improving the lives of cancer patients

Click here to­ read full press release/ article | Ref: Genmab | Image: Genmab